149 related articles for article (PubMed ID: 38186850)
1. Pyruvate carboxylase deficiency type C; variable presentation and beneficial effect of triheptanoin.
Bernhardt I; Van Dorp L; Dixon M; McSweeney M; Gan C; Baruteau J; Chakrapani A
JIMD Rep; 2024 Jan; 65(1):10-16. PubMed ID: 38186850
[TBL] [Abstract][Full Text] [Related]
2. Clinical, biochemical and molecular characterization of 12 patients with pyruvate carboxylase deficiency treated with triheptanoin.
Lasio MLD; Leshinski AC; Ducich NH; Flore LA; Lehman A; Shur N; Jayakar PB; Hainline BE; Basinger AA; Wilson WG; Diaz GA; Erbe RW; Koeberl DD; Vockley J; Bedoyan JK
Mol Genet Metab; 2023 Jun; 139(2):107605. PubMed ID: 37207470
[TBL] [Abstract][Full Text] [Related]
3. Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoin.
Breen C; White FJ; Scott CA; Heptinstall L; Walter JH; Jones SA; Morris AA
Eur J Pediatr; 2014 Mar; 173(3):361-6. PubMed ID: 24114256
[TBL] [Abstract][Full Text] [Related]
4. Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy.
Hadera MG; Smeland OB; McDonald TS; Tan KN; Sonnewald U; Borges K
J Neurochem; 2014 Apr; 129(1):107-19. PubMed ID: 24236946
[TBL] [Abstract][Full Text] [Related]
5. Triheptanoin for the treatment of brain energy deficit: A 14-year experience.
Mochel F
J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy.
Mochel F; DeLonlay P; Touati G; Brunengraber H; Kinman RP; Rabier D; Roe CR; Saudubray JM
Mol Genet Metab; 2005 Apr; 84(4):305-12. PubMed ID: 15781190
[TBL] [Abstract][Full Text] [Related]
7. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
8. Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis.
Tefera TW; Wong Y; Barkl-Luke ME; Ngo ST; Thomas NK; McDonald TS; Borges K
PLoS One; 2016; 11(8):e0161816. PubMed ID: 27564703
[TBL] [Abstract][Full Text] [Related]
9. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.
Pascual JM; Liu P; Mao D; Kelly DI; Hernandez A; Sheng M; Good LB; Ma Q; Marin-Valencia I; Zhang X; Park JY; Hynan LS; Stavinoha P; Roe CR; Lu H
JAMA Neurol; 2014 Oct; 71(10):1255-65. PubMed ID: 25110966
[TBL] [Abstract][Full Text] [Related]
10. Triheptanoin alters [U-
McDonald T; Hodson MP; Bederman I; Puchowicz M; Borges K
J Cereb Blood Flow Metab; 2020 Mar; 40(3):678-691. PubMed ID: 30890077
[TBL] [Abstract][Full Text] [Related]
11. Induced pluripotent stem cell-derived hepatocytes reveal TCA cycle disruption and the potential basis for triheptanoin treatment for malate dehydrogenase 2 deficiency.
Mathis D; Koch J; Koller S; Sauter K; Flück C; Uldry AC; Forny P; Froese DS; Laemmle A
Mol Genet Metab Rep; 2024 Jun; 39():101066. PubMed ID: 38425868
[TBL] [Abstract][Full Text] [Related]
12. The odd-carbon medium-chain fatty triglyceride triheptanoin does not reduce hepatic steatosis.
Comhair TM; Garcia Caraballo SC; Dejong CH; Lamers WH; Koehler SE
Clin Nutr; 2017 Feb; 36(1):229-237. PubMed ID: 26778339
[TBL] [Abstract][Full Text] [Related]
13. Triheptanoin - Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency.
Laemmle A; Steck AL; Schaller A; Kurth S; Perret Hoigné E; Felser AD; Slavova N; Salvisberg C; Atencio M; Mochel F; Nuoffer JM; Gautschi M
Mol Genet Metab Rep; 2021 Dec; 29():100814. PubMed ID: 34712577
[TBL] [Abstract][Full Text] [Related]
14. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
15. Triheptanoin Mitigates Brain ATP Depletion and Mitochondrial Dysfunction in a Mouse Model of Alzheimer's Disease.
Yuan X; Wang L; Tandon N; Sun H; Tian J; Du H; Pascual JM; Guo L
J Alzheimers Dis; 2020; 78(1):425-437. PubMed ID: 33016909
[TBL] [Abstract][Full Text] [Related]
16. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
Schwarzkopf TM; Koch K; Klein J
Neuroscience; 2015 Aug; 300():201-9. PubMed ID: 25982559
[TBL] [Abstract][Full Text] [Related]
17. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
Vockley J; Longo N; Madden M; Dwyer L; Mu Y; Chen CY; Cataldo J
Clin Nutr ESPEN; 2021 Feb; 41():293-298. PubMed ID: 33487279
[TBL] [Abstract][Full Text] [Related]
18. A Rare Case of Type B Neonatal Pyruvate Carboxylase Enzyme Deficiency Presenting With Refractory Lactic Acidosis in the Early Neonatal Period.
Sharif S; Velumula PK; Boddu PK; Altinok D; Fernandes N
Cureus; 2022 Oct; 14(10):e29903. PubMed ID: 36348915
[TBL] [Abstract][Full Text] [Related]
19. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
